Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
The Food and Drug Administration (FDA) is charged with protecting the general health and well being of Americans with medicines and certain treatment equipment. Sometimes these medications or treatment equipment fail, don't work as indicated or cause serious, life threatening side effects. Reporting these events is important so the FDA can track and monitor these [...]
Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival. According to a study published online ahead of print in the Journal of Clinical Oncology. by Amir Goldkorn, MD, and colleagues at the Keck School of Medicine of [...]
